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Available online 14 January 2014Abstract The BIRC5 gene encodes the oncofetal protein SURVIVIN, as well as four additional splice variants (ΔEx3, 2B, 3B and
2α). SURVIVIN, an inhibitor of apoptosis, is also a chromosomal passenger protein (CPP). Previous results have demonstrated
that SURVIVIN is expressed at high levels in embryonic stem cells and inhibition of SURVIVIN function results in apoptosis,
however these studies have not investigated the other four splice variants. In this study, we demonstrate that all variants are
expressed at significantly higher levels in human embryonic stem (hES) cells than in differentiated cells. We examined the
subcellular localization of the three most highly expressed variants. SURVIVIN displayed canonical CPP localization in mitotic
cells and cytoplasmic localization in interphase cells. In contrast, SURVIVIN–ΔEx3 and SURVIVIN–2B did not localize as a CPP;
SURVIVIN–ΔEx3 was found constitutively in the nucleus while SURVIVIN–2B was distributed along the chromosomes during
mitosis and also to the mitotic spindle poles. We used inducible shRNA against SURVIVIN to inhibit expression in a titratable
fashion. Using this system, we reduced the mRNA levels of these three variants to approx. 40%, resulting in a concomitant
reduction of OCT4 and NANOG mRNA, suggesting a role for the SURVIVIN variants in pluripotency.
© 2014 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction vital in cell proliferation (Carmena et al., 2012). It is also theThe oncofetal protein SURVIVIN functions as a requisitemember
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http://dx.doi.org/10.1016/j.scr.2014.01.002smallest member of the inhibitor of apoptosis (IAP) family of
proteins (Ambrosini et al., 1997). While absent in most adult
tissues, SURVIVIN is highly expressed and required during early
mammalian development (Adida et al., 1998; Uren et al.,
2000), and has similarly been shown to be highly expressed in
human (Blum et al., 2009; Filion et al., 2009) and mouse
embryonic stem cells (hES and mES respectively) (Coumoul et
al., 2004) which recapitulate the early embryo phenotype. In
addition to embryonic stem cells, it is expressed and required in
several somatic stem cell types (Gheisari et al., 2009; Leung et
al., 2007; Marconi et al., 2007; Zhang et al., 2001) suggesting
that it may play a broad, still unknown role in stem cell biology.er B.V. All rights reserved.
540 A.N. Mull et al.SURVIVIN is the product of the BIRC5 gene and along
with canonical SURVIVIN the pre-mRNA is alternatively spliced
into four variants, SURVIVIN–ΔEx3 (ΔEx3), SURVIVIN–2B (2B)
(Mahotka et al., 1999), SURVIVIN–3B (3B) and SURVIVIN–2α
(2α) (Caldas et al., 2005) resulting in transcripts with varied
functional domains (Fig. 1A). Although highly investigated in
cancer cell lines (for rev. Altieri (2003)), little is known
about the normal levels of expression, localization or
functional roles of these variants in non-cancerous cells. In
this manuscript we demonstrate that all five variants are
expressed in hES cells at higher levels in comparison to
differentiated cell types. We also demonstrate that SURVIVIN,
ΔEx3 and 2B have distinct localization patterns within the cell.
As mentioned above, SURVIVIN is an inhibitor of apoptosis
and is necessary for cell proliferation. In somatic cells inhibition
of SURVIVIN results in increased apoptosis and reduced cell
proliferation. Similarly, studies in human and mouse ES cells
have demonstrated that inhibition of SURVIVIN results in
increased apoptosis (Blum et al., 2009; Coumoul et al., 2004;
Filion et al., 2009) and also blocked the formation of teratomas
following transfer of hES cells to immunocompromised mice
(Blum et al., 2009). Recent evidence suggests that SURVIVIN
and/or its splice variants may have additional roles in cells
beyond the classically described CPP and apoptosis inhibition.
SURVIVIN has been demonstrated to upregulate human telome-
rase (hTERT) in colon cancer cells by enhancing activity of MYCFigure 1 Characterization of SURVIVIN splice variant expression
SURVIVIN pre-mRNA transcript demonstrating four primary exons (A
cryptic exons (2B and 3B) and their corresponding translated protein
types. Values are relative to canonical SURVIVIN expression in hES c
cells and two differentiated cell lines normalized to expression leve
OCT4 and NANOG in hES cells, ES-MSCs and HDF. α-TUBULIN is sho
Repeat); NES (nuclear export signal); NLS (nuclear localization signaand SP1 in an AURORA B dependent fashion (Furuya et al., 2009)
and in colonic crypts, inhibition of SURVIVIN is required for the
progression of differentiation (Zhang et al., 2001). SURVIVIN has
recently been demonstrated to bind to STAT3 and influence the
transcription of STAT3 targets (Wang et al., 2010). Homozygous
knock-out of SURVIVIN in hematopoietic stem cells (HSCs)
results in loss of the hematopoietic compartment, while HSCs
heterozygous for SURVIVIN survive and produce all cell lineages
excluding erythroid cells (Leung et al., 2007) suggesting that
SURVIVIN dosagemay be important for its function. To elucidate
the effects of SURVIVIN dosage in hES cells, we used an inducible
shRNA system to inhibit SURVIVIN in a controlled fashion. We
were able to inhibit SURVIVIN expression in a dose dependent
manner while still maintaining cell survival and proliferation.
Additionally, inhibited cells had decreased expression of the
pluripotency regulators OCT4 and NANOG suggesting that
SURVIVIN or its splice variants may have a role in maintaining
pluripotency.2. Materials and methods
2.1. Cell culture
Human ES cells, WA09 (WiCell Research Institute, Madison,
WI, http://www.wicell.org) were cultured on dishes coatedin human embryonic stem cells. (A) Pictorial representation of
dida et al., 1998; Altieri, 2003; Ambrosini et al., 1997) and two
domains in each variant. (B) qRT-PCR expression levels in 3 cell
ells. (C) Expression levels of each SURVIVIN splice variant in hES
l in hES cells. (D) Western blot detection of canonical SURVIVIN,
wn as a loading control. BIR (Baculovirus Inhibitor of apoptosis
l); *p b .05, **p b .001.
541A Role for the Oncofetal Protein SURVIVIN in Pluripotencyfor at least 2 h with Matrigel (BD Biosciences, http://www.
bdbiosciences.com). hES cell media containing 80% knockout
Dulbecco's modified eagle medium (DMEM), 20% knockout
serum replacer, 1% nonessential amino acids, 1% penicillin/
streptomycin (100 U per 100 μg/ml), 2 mM L-glutamine
(all from Invitrogen, Carlsbad, CA, http://www.invitrogen.
com) and 4 ng/ml basic fibroblast growth factor (bFGF,
ReproCELL, San Jose, CA, http://www.reprocell.net) was
pre-conditioned by culture with inactivated mouse embry-
onic fibroblasts (MEF; Millipore, Billerica, MA, http://www.
millipore.com) and collected every two days. hES cell lines
were cultured with human conditioned media (HuCM)
supplemented with 4 ng/ml bFGF and transduced hES cell
line media containing 2 ng/ml puromycin (Sigma-Aldrich, St.
Louis, http://www.sigmaaldrich.com). hES cells were main-
tained by weekly manual passaging or bulk passaging
using 1 mg/ml Collagenase IV (Invitrogen). hES cells were
plated for experiments using Accutase (Fisher, Pittsburgh,
PA, http://www.fishersci.com) and plated at a density of
26,000 cells/cm2. Retinoic acid (RA) experiments were
conducted by culturing hES cells in HuCM supplemented
with 10 μm RA (ACROS Organics, New Jersey, http://www.
acros.com) and samples were collected every three days
using Accutase. hES cell-derived mesenchymal stem cells
(MSCs) were generated as previously described (Hwang et
al., 2008) and sorted via autoMACS using MSC marker CD 105
magnetic beads (Miltenyi Biotec, Germany, http://www.
miltenyibiotec.com). Human dermal fibroblasts were cul-
tured in CF-1 media, 90% DMEM high glucose, 10% Certified
FBS (heat inactivated), 1% 2 mM L-glutamine, 1% MEM
non-essential amino acids, and 1% pen/strep (100 U per
100 μg/ml) all from Invitrogen.2.2. shRNA constructs
Custom vectors were designed either in a pLKO-puro-IPTG-
3xLacO vector containing shRNA sequences (Sigma Aldrich) or
the TRIPZ tetracycline inducible vector (Open Biosystems). The
DNA sequences targeting SURVIVIN transcripts were as follows:
5′-CCGCATCTCTACATTCAAGAA-3′, (designated as Sh18); 5′-CCT
TTCTGTCAAGAAGCAGTT-3′, (Sh20); a non target sequence
(ShNT); 5′-TGGCCCAGTGTTTCTTCTGCTT-3′ (Sh1) and 5′-CCC
TTAGCAATGTCTTAGGAAA-3′ (Sh4). Lentiviral particles contain-
ing these vectors were purchased from the manufacturer and
incubated for 2 h with WA09 (WiCell) hES cells in a single
cell suspension in standard cell culture incubation condi-
tions (37 °C, 5.0% CO2, in a humidified incubator). A second
volume of virus particles was added and the cells were
plated onto Matrigel-coated cell culture wells overnight. Fresh
human conditioned stem cell media (HuCM) was applied and
cells were fed every two days until colonies were observed.
Colonies were then hand passaged and maintained with HuCM
containing 2 μg/ml puromycin (Sigma-Aldrich) designated as
Puro-HuCM. Cells were prepared for experimental treatments
using Accutase (Invitrogen) and seeded at 26,000 cells/cm2 in
Puro-HuCM with 250 μM IPTG to induce transcription of the
shRNA. Control and experimental cells were treated with fresh
Puro-HuCMwith and without IPTG every 24 h for a total of 72 h.
Cells were then collected and analyzed following previously
described real time PCR, western blot, or immunocytochemistry
protocols.2.3. Flow cytometry of annexin V
Sh18 cells were treated following protocol outlined in Section
2.2. Cells were treated for 72 h with either 250 μM or 2.5 mM
IPTG. Negative control cells were not treated and positive
control cells were treated for 7 h with 20 μM camptothecin
(BioVision, http://www.biovision.com, Milpitas, CA). Live
cells were then collected and labeled for Annexin V following
the manufacturer's instructions (BioLegend, http://www.
biolegend.com, San Diego, CA). Annexin-FITC expression was
analyzed using flow cytometry on a FACSCalibur (BD Biosci-
ences, San Jose, CA, http://www.bdbiosciences.com) and
Accuri C6 (BD Biosciences) and data was processed using
FlowJo software (Tree Star Inc., Ashland, OR, http://www.
flowjo.com).
2.4. Real time polymerase chain reaction
Total cellular RNA was extracted from cells using TRIzol
(Invitrogen) and DNAase treated with the DNA-free kit
(Ambion, Austin, TX, http://www.ambion.com) following
manufacturer's directions for stringent conditions. RNA was
dialyzed for 30 min against milliQwater, 10 mM Tris and 1 mM
EDTA adjusted to pH 7.5 with HCL (all from Fisher). cDNA was
synthesized using GeneAmp RNA PCR kit from Applied
Biosciences (Fisher) and no-RT reactions were performed
without reverse transcriptase and RNAase inhibitor enzymes.
One microgram of RNA was used, following the manufacturer's
directions. Quantitative real time polymerase chain reaction
(qPCR) was performed to determine relative mRNA expression
levels. Expression fold changes were calculated using the ΔΔCt
method and normalized using the housekeeping gene, β-ACTIN
as an internal control. Taqman master mix and gene assays
with water only were used as a negative control. mRNA
expression assays were analyzed in a triplicate PCR reaction
with no-RT negative controls and each experiment was
performed at least three independent times. Statistical
analyses were performed to identify statistically significant
differences (p b 0.05) using one way ANOVA and Tukey's post
hoc analysis. Primers were selected from predeveloped
Applied Biosystems TaqMan Assays, which are pre-designed
qPCR primers and TaqMan MGB probes; Oct-4 (Hs01895061_u1)
and Nanog (Hs02387400_g1). SURVIVIN splice variant specific
primers and probe sequences were used as described in
Marconi et al. (2007) and listed in Supplemental Table 1.
2.5. Immunocytochemistry
Human ES cells were grown on plastic coverslips pre-treated
with Matrigel. Coverslips were rinsed with PBS and fixed for
at least 30 min in 2% formaldehyde, and permeabilized in
0.1% Triton X-100 in phosphate-buffered saline (PBST; all
reagents from Fisher). Primary and secondary antibody incuba-
tions were performed and cover slips were mounted as
previously described (Momcilovic et al., 2009). Primary anti-
bodies SURVIVIN, SURVIVIN–2B, and SURVIVIN–ΔEx3 (Abcam,
Cambridge, U.K., http://www.abcam.com), NANOG (Cell
Signaling, http://www.cellsignal.com) and α-TUBULIN (Sigma-
Aldrich, St. Louis, http://www.sigmaaldrich.com)were applied
for 40 min. Primary antibodies were detected using species-
specific fluorescently labeled secondary antibodies (Invitrogen)
542 A.N. Mull et al.at 37 °C for 40 min and coverslips were mounted onto glass
slides using Vectashield mounting medium with DAPI to label
DNA (Vector Laboratories, Burlingame, CA, http://www.
vectorlabs.com). Images were taken using Deltavision Personal
DV microscope. Colocalization analysis was performed using
ImageJ Software (http://rsbweb.nih.gov/ij/), with threshold
settings of 125 and intensity ratio of 50%.
2.6. Western blot analysis
Cells were collected using Accutase (Invitrogen), washed twice
with phosphate-buffered saline (PBS, Invitrogen) then lysed on
ice using IP lysis buffer (0.025 M Tris, 0.15 M NaCl, 0.001 M
EDTA, 1% NP–40, 5% glycerol; pH 7.4, with Halt Protease
and Phosphatase Inhibitor cocktail (Thermo Scientific, Rock-
ford, IL, http://www.piercenet.com). Six micrograms of total
protein was analyzed under reducing conditions on 12% precast
polyacrylamide gels (NuPAGE, Invitrogen) followed by transfer
to polyvinylidene difluoride membrane (Fisher) then blocked
at room temperature for 1 h with 1% BSA (Sigma-Aldrich) in TBS
with 0.1% Tween-20 (Fisher). Primary antibodies, Survivin
(Abcam) and α-tubulin (Sigma-Aldrich) were applied to mem-
brane and incubated at 4 °C overnight. Horseradish peroxidase-
conjugated species-specific secondary antibodies (Invitrogen)
were diluted in TBS with 0.1% Tween-20 buffer and incubated
at room temperature for 1 h. ECL Advance Western Blotting
Detection kit (Fisher) was used according to the manufacturer's
directions and chemiluminescence was recorded on ECL film
(Fisher).
3. Results
3.1. Human embryonic stem cells express five
SURVIVIN splice variants
Global gene expression analysis demonstrated that SURVIVIN is
highly expressed in hES cells (Blum et al., 2009), however the
expression of the remaining splice variants had not previously
been examined. SURVIVIN pre-mRNA contains four primary
exons (Adida et al., 1998; Altieri, 2003; Ambrosini et al., 1997)
and two cryptic exons (2B and 3B) (Fig. 1A), resulting in diverse
protein domains rendering unique subcellular localization and
function (Fig. 1A). Translated canonical SURVIVIN contains a BIR
domain (Ambrosini et al., 1997) critical for its anti-apoptotic
function, a nuclear export sequence (NES) domain for
binding to the nuclear export protein CRM1 (Rodriguez et al.,
2002; Stauber et al., 2006), a SURVIVIN dimerization domain
(Chantalat et al., 2000; Verdecia et al., 2000) and a c-terminal
amphipathic α-helix used for protein–protein interactions
(Jeyaprakash et al., 2007). ΔEx3 mRNA contains exons 1,2 and
4, however a frameshift occurs upon removal of exon 3 resulting
in a novel translation of exon 4 containing a bipartite nuclear
localization signal (NLS) (Mahotka et al., 2002). 2B contains all
four primary exons but additionally includes a cryptic exon (2B)
between exons 2 and 3. This insertion truncates the BIR domain
and as a result 2B has reduced anti-apoptotic ability (Mahotka
et al., 1999). Thus, changes in translated domains result in
alterations to subcellular localization and function amongst the
splice variants.
To determine which alternatively spliced SURVIVIN
variants hES cells express, we used reverse transcriptasePCR (RT-PCR) with exon specific primers. We detected mRNA
expression for canonical SURVIVIN, ΔEx3, 2B, 3B, and 2α in
hES cells (Supplemental Fig. 1). Using quantitative RT-PCR
(qRT-PCR) and primer and probe sets specific for each splice
variant (Supplemental Table 1, Marconi et al., 2007) we
quantified the relative expression of each variant in hES cells
(Fig. 1B). Canonical SURVIVIN was the highest expressed
variant followed by ΔEx3, which was expressed at 36% of the
level of SURVIVIN. The next most expressed variant was 2B,
which was expressed at 6% when compared to SURVIVIN.
Expressions of 3B and 2α were both less than 3% when
compared to SURVIVIN.3.2. Expression of the SURVIVIN splice variants is
uniformly high in hES cells when compared to more
differentiated cell types
Functions for the alternative splice variants have been
described during development (Caldas et al., 2007; Jiang et
al., 2005; Zwerts et al., 2007) and relative expression of the
variants changes during keratinocyte differentiation (Marconi
et al., 2007). To determine if the relative splice variant
expression changes during differentiation we differentiated
hES cells to mesenchymal stem cells (hESd–MSC) using a
published protocol (Hwang et al., 2008). RNA and protein
samples from hES cells, hESd–MSCs as well as primary human
dermal fibroblasts (HDFs) were collected and analyzed.
qRT-PCR revealed significantly higher levels of all SURVIVIN
splice variants in hES cells when compared to levels detected
in hESd–MSCs and HDFs (Figs. 1B, C). Fig. 1B demonstrates
levels of each variant detected in all three cell types
(normalized to expression levels detected for canonical
SURVIVIN in hES cells) and demonstrates that in the differen-
tiated cells the splice variants follow the same basic
expression pattern with SURVIVIN detected at the highest
levels, followed by ΔEx3, 2B, 3B and then 2α. Very similar
expression levels of each variant were detected in hESd–MSCs
and HDFs (Fig. 1C) and each was expressed at significantly
lower levels than those observed in hES cells. Western blotting
detected robust expression of SURVIVIN protein in hES cells
(Fig. 1D) but greatly reduced protein expression in hESd–
MSCs. SURVIVIN was not detectable in HDFs following loading
of equal amounts of total protein. Splice variant specific
antibodies suitable for western blotting detection of endog-
enous protein are not available so we could not compare
protein levels for the individual splice variants. In confirma-
tion of both the pluripotent and differentiated phenotypes,
the pluripotent transcription factors OCT4 and NANOG were
detected by mRNA (not shown) and protein (Fig. 1D) in hES
cells but not in hESd–MSCs or HDFs.
To further verify the relative expression of the variants
observed following directed differentiation, we evaluated
the expression of each variant during retinoic acid induced
differentiation. Human ES cells were treated with 10 μM
retinoic acid (RA) for 12 days and hES cells were collected
every three days. Similar to the previous experiment qRT-PCR
revealed significantly higher levels of all SURVIVIN splice
variants in untreated hES cells when compared to RA treated
cells (Supp. Fig. 2B). The expression of all variants rapidly
declined during differentiation mirroring the results observed
for OCT4 and NANOG. SURVIVIN, ΔEx3, and 2B relative
543A Role for the Oncofetal Protein SURVIVIN in Pluripotencyexpression decreased and stayed low while the levels of 3B
and 2α fluctuated relative to their expression in undifferen-
tiated hES cells (Supp. Fig. 2B). At each examined day theFigure 2 Subcellular localization of SURVIVIN, ΔEx3 and 2B during i
and DNA at interphase (A–C) and metaphase (D–F). (G–L) SURVIVINΔE
(M–R) SURVIVIN–2B, α-TUBULIN and DNA at interphase (M–O) and met
Arrows, 2B localization to the mitotic spindle poles. Blue = DNA; green
red = SURVIVIN (C, F), ΔEx3 (I, L) and 2B (O, R). Bars = 10 μm.same basic expression pattern was observed. SURVIVIN was
detected at the highest levels, followed by ΔEx3, 2B, 3B and
then 2α (Supp. Fig. 2A).nterphase and metaphase. (A–F) Canonical SURVIVIN, α-TUBULIN
x3, α-TUBULIN and DNA at interphase (G–I) and metaphase (J–L).
aphase (P–R). Arrowhead, 2B localization to the metaphase plate.
= α-TUBULIN; white = SURVIVIN (B, E), ΔEx3 (H, K) and 2B (N, Q);
544 A.N. Mull et al.3.3. HumanES cells demonstrate disparate localization
amongst individual SURVIVIN splice variants
Previous studies utilizing overexpression of fluorescently
labeled proteins have indicated that distinct from canonical
SURVIVIN, ΔEx3 and 2B do not localize as chromosomal
passenger proteins and instead display differential localization
throughout the cell cycle in somatic cells. No previous study has
examined the localization of any splice variants in embryonic
stem cells. We chose to focus on the subcellular localization of
SURVIVIN, ΔEx3 and 2B in hES cells (Fig. 2, Supplemental Figs.
3–5). These three variants represent approximately 98% of the
mRNA expression from the BIRC5 gene in hES cells and
antibodies exist that distinguish these three variants from
each other. During interphase, SURVIVIN is found in both the
cytoplasm and the nucleus (Fig. 2B, also shown in context
with more cell cycle stages in Supp. Fig. 3B). It is diffuse in the
cytoplasm and primarily localized to bright foci within the
nucleus. After nuclear envelope breakdown in prophase,
SURVIVIN is no longer diffuse and only found at the centromeres
of the aligning chromosomes (Supp. Fig. 3E) particularly those
centromeres of unaligned chromosomes (Supp. Fig. 3E, arrow).
At metaphase, SURVIVIN is distributed both at the centromeres
and the intercentromeric region (Fig. 2E, Supp. Fig. 3H),
consistent with its function as a chromosomal passenger protein
(CPP). SURVIVIN is found on the interzonal microtubules during
anaphase (Supp. Fig. 3K).
By contrast, ΔEx3 is found almost exclusively in the nucleus
during interphase (Fig. 2H, Supp. Fig. 4B) and it is excluded from
the prominent nucleoli found in hES cells. During prophase, it
remains in the nucleus until nuclear envelope breakdown and
never localizes to the centromeres as does SURVIVIN (Supp. Fig.
4E). At metaphase, ΔEx3 does not localize as a CPP and is
excluded from the condensed chromosomes as evidenced by the
negative staining in Fig. 2K (arrow, Supp. Fig. 4H). Finally, ΔEX3
does not show any localization to the interzonalmicrotubules at
telophase (Supp. Fig. 4K) but instead is broadly distributed
throughout the cytoplasm.
SURVIVIN–2B was only faintly detected in hES cells. During
interphase, 2B clearly delineated the nucleus but alsowas found
in the cytoplasm (Fig. 2N, Supp. Fig. 5B). It was distributed
throughout the nucleus with no signs of exclusion from the
nucleoli as was the case for ΔEx3. At prophase, it is distributed
diffusely throughout the cytoplasm (Supp Fig. 5E). At meta-
phase, it is found concentrated on the condensed chromosomes
(Fig. 2Q, arrowhead, Supp. Fig. 5H). It appears to localize along
the length of the chromosomes with no apparent centromeric
concentration as would be expected of a CPP. Additionally, it is
also found at the mitotic spindle poles (Fig. 2Q, arrows, Supp.
Fig. 5H). This is consistent with a report that overexpressed
SURVIVIN–2B–GFP fusion proteins localized to the centrosome
and impacted microtubule nucleation in HEK293 cells (Ling et
al., 2007. However, to the best of our knowledge, this is the first
time endogenously expressed 2B has been localized to the
centrosome in any cell type.3.4. Inhibition of SURVIVIN mRNA results in a
concomitant decrease in OCT4 mRNA expression
Leung et al. (2007) demonstrated that homozygous knock-out of
SURVIVIN in the hematopoietic system resulted in widespreadloss of hematopoiesis. Surprisingly heterozygous mice were
mostly unaffected but a subset of mice had defects in
erythropoiesis, concluding that a dosage effect of SURVIVIN
expression exists in these cells. To test if a similar dosage effect
was detectable in human embryonic stem cells we used a
doxycycline (Dox) inducible shRNA system to inhibit SURVIVIN
expression in a titratable fashion.We transduced hES cells with a
lentiviral shRNA construct and selected stable integrants using
puromycin. As shown in Fig. 3A when we added Dox for 48 h
we were able to inhibit SURVIVIN mRNA expression in a dose
dependent fashion. Addition of 0.3 μM Dox or 1.0 μM Dox
resulted in a statistically significant (p b 0.05) decrease in
SURVIVIN mRNA expression. As noted above, SURVIVIN is highly
expressed in the early embryo and in numerous stem cells. This
led us to hypothesize that elevated expressionmay facilitate the
pluripotent phenotype in hES cells. To test this we inhibited
SURVIVIN translation and examined expression of the core
pluripotency transcription factor OCT4. A concomitant decrease
in expression of OCT4 mRNA was observed when SURVIVIN was
inhibited (Fig. 3A). Human ES cells have demonstrated ability to
silence exogenous gene expression (Stewart et al., 2008) and we
observed a similar result. After transduction, cell lines were
continuously maintained under puromycin selection. Experi-
ments were initiated after 6, 14, and 19 passages. At each of
these passages cell lineswere treatedwith Dox for 72 h and then
collected for mRNA and protein analyses. Despite growth under
constant puromycin selection, as passage number increased the
cells lost the ability to decrease SURVIVIN mRNA expression in
response to Dox induction (Fig. 3B). Simultaneously, the cells
lost the ability to inhibit OCT4 expression suggesting that OCT4
inhibition is a direct result of inhibiting SURVIVIN expression and
not a nonspecific reaction to Dox treatment.
We did notice a slight depression of SURVIVIN and OCT4
expression in control hES cells treated with 1 μM Dox for
72 h (Supp. Fig. 6A). This decrease was not statistically
significant but to remove this minor concern and further
evaluate this finding we developed three new cell lines
(Sh18, Sh20 and a non-target control ShNT) in which shRNA
expression was controlled by the Lac operon. Treatment of
control hES cells with 250 μM IPTG did not affect SURVIVIN
and OCT4 (Supp. Fig. 6A) mRNA expression. Furthermore,
SURVIVIN inhibition did not cause a significant increase in
apoptosis (Supp. Figs. 6B, C) even when 2.5 mM IPTG was
added (10× the levels used in other experiments). As shown
in Fig. 4, IPTG induction resulted in a statistically significant
reduction of SURVIVIN expression to approx. 40% of control
in both Sh18 and Sh20 cell lines. Sh1 (Dox inducible) is shown
for comparison. Treatment with IPTG also dramatically
reduced SURVIVIN protein expression assayed by western
blot (Fig. 4B). IPTG treatment of the parent cell line (WA09)
or of ShNT did not result in a change to SURVIVIN protein
levels.3.5. All splice variants are inhibited by
shRNA expression
Using splice variant specific qRT-PCR we examined the
effect of shRNA expression on each variant. SURVIVIN, ΔEx3
and 2B showed the greatest inhibition with each variant
being inhibited to approx 40% of control levels in Sh18 and
Sh20 cell lines. SURVIVIN–3B and SURVIVIN–2α were also
Figure 3 Doxycycline (Dox) inducible shRNA inhibition of SURVIVIN. (A) hES cells stably transduced with the Dox inducible ShRNA,
Sh1, were treated with 0.3 μM Dox or 1.0 μM Dox for 48 h. (B) hES cells stably transduced with the Dox inducible Sh4 ShRNA, treated
with 1.0 μM Dox for 72 h exhibit silencing over subsequent passaging. *p b .05.
545A Role for the Oncofetal Protein SURVIVIN in Pluripotencyinhibited although to a reduced extent. The Sh1 Dox
inducible shRNA also inhibited these variants. In all three
cell lines OCT4 expression was reduced significantly. NANOG
expression was also reduced in all three cell lines but only
two lines (Sh18 and Sh20) reached statistical significance.
Interestingly, there was some variability between cell lines
in the extent of inhibition of these pluripotent factors
perhaps due to the extent of inhibition to specific SURVIVIN
variants. Despite the decrease in mRNA for OCT4 and
NANOG, no significant decrease in protein levels were
observed (not shown) after three days of shRNA induction.
We have previously noted discordance between OCT4 and
NANOG mRNA levels and protein expression (Momcilovic etFigure 4 Inducible shRNA inhibits all SURVIVIN splice variants as w
transduced hES cell lines were analyzed by qRT-PCR. Cell lines were
Sh20). (B) Western blot detection of SURVIVIN in Sh18 and control cal., 2009). Longer term IPTG induction (12 days) resulted in
a more differentiated morphology, a reduction in NANOG
protein levels and an increase in the number of cells which
don't express NANOG assayed by immunocytochemistry
(Supp. Fig. 7).4. Discussion
SURVIVIN expression is high in the early embryo (Adida et al.,
1998; Uren et al., 2000), diminishes during fetal development
and it is essentially undetectable in adult tissues with the
exception of cancer cells in which SURVIVIN is almost uniformlyell as core pluripotency regulators OCT4 and NANOG. (A). Stably
treated with 1.0 μM Dox (Sh1) or 250 μM IPTG (ShNT, Sh18 and
ells. *p b .05, **p b .001.
546 A.N. Mull et al.expressed (reviewed in Altieri, 2003; F. Li, 2005) and for this
reason SURVIVIN is a target for clinical interventions (reviewed
by Kelly et al. (2011)). SURVIVIN is also expressed and/or
required in several somatic stem/progenitor cell types
(Gheisari et al., 2009; Leung et al., 2007; Marconi et al.,
2007; Zhang et al., 2001), suggesting that it may also play a
broad role in all stem cells. Our results (Fig. 1) and those of
others show SURVIVIN to be highly expressed in hES cells (Blum
et al., 2009). In our study, canonical SURVIVIN was expressed
approximately nine fold higher than differentiated cell types.
This difference is likely not simply attributed to proliferation
disparities as all cells were in logarithmic growth and didn't
have a significant difference in mitotic index (not shown).
SURVIVIN protein was readily detected in hES cells by western
blotting at significantly higher levels than observed in hESd–
MSCs and dermal fibroblasts.
We extended our observations to include the mRNA
expression of the SURVIVIN splice variants, ΔEx3, 2B, 3B and
2α, which we first confirmed are expressed in hES cells. These
variants are also highly expressed in hES cells relative to more
differentiated cells. In our differentiated cell types (MSCs,
HDFs, and RA induced cells) we observedmuch lower expression
of all variants when compared to hES cells. This change in
expression was rapid, occurring within 3 days of RA treatment.
In the only other stem cell type in which these variants have
been examined, Marconi et al. (2007) demonstrated that
keratinocyte stem cells expressed all five variants but that
SURVIVIN, ΔEx3 and 2B were predominant and expressed at
similar levels to each other. In contrast, our results demon-
strated that canonical SURVIVIN was expressed at higher levels
than ΔEx3which was in turn expressed at higher levels than 2B.
Marconi et al. (2007) demonstrated that during keratinocyte
differentiation the expression of these variants changed so that
in the transient amplifying and post mitotic cells, 2B and 2α
were the most predominant forms with the other three variants
essentially not expressed. However, we did not observe a
similar switch in our differentiated cell lines. All three lines
retained the same relative expression between the splice
variants while overall expression of all variants diminished in
the differentiated cells. None of the cells we examined
progressed to a post-mitotic phenotype as did the cells in
Marconi et al. (2007) and this may explain the discrepancy
between these two studies. Our results are consistent with
those observed by Blum et al. (2009). These authors examined
canonical SURVIVIN expression and showed that cells differen-
tiated in embryoid bodies expressed much less SURVIVIN than
pluripotent ES cells.
Using specific antibodies for SURVIVIN, ΔEx3 and 2B we
identified the subcellular distribution of these three splice
variants within hES cells. SURVIVIN has classical CPP localization
in hES cells consistent with that observed in other cell types
(Noton et al., 2006; Uren et al., 2000). In contrast, ΔEx3
predominantly localized diffusely in the nucleus, but was not
observed in the nucleoli. This localization pattern is consistent
with previous results of GFP–ΔEx3 fusion proteins in cancer cells
(Noton et al., 2006; Song and Wu, 2005). Song and Wu (2005)
also demonstrated that the lack of ΔEx3 in the nucleolus is due
to ΔEx3 being actively broken down in a proteosome dependent
manner at the nucleolus. We did not address this specific
question but our data are consistent with a similar mechanism
occurring in hES cells. In vitro studies of protein binding and in
vivo GFP labeled ΔEx3 demonstrate that ΔEx3 cannot functionas a CPP (Noton et al., 2006) and our results during mitosis are
consistent with this finding. SURVIVIN–2B localizes to the
cytoplasm (Mahotka et al., 2002) but does not localize as a
CPP. Overexpression of a 2B–GFP fusion protein demonstrated
localization to the mitotic spindle poles (Ling et al., 2007) and
we observed a similar localization in hES cells. Our results are
the first time this has been observed from endogenous
expression of 2B and is likely due to the elevated expression in
hES cells. Due to its high expression level in hES cells,
SURVIVIN-2B may have a function in these cells that it does
not have in differentiated cells.
Strong SURVIVIN expression was previously observed in hES
cells and the teratomas derived from these cells but not in
embryoid bodies (Blum et al., 2009). Expression of a dominant
negative SURVIVIN mutant (T34A) which is not able to be
phosphorylated by CDK1 resulted in the absence of teratoma
formation and increased cell death. Inhibition of SURVIVIN
by siRNA (Blum et al., 2009) or shRNA (Filion et al., 2009) in
these same cells had a similar result. In mouse ES cells shRNA
inhibition of Survivin resulted in decreased cell survival
(Coumoul et al., 2004). Knockout of Survivin is early embryonic
lethal (Uren et al., 2000) therefore in systems inwhich SURVIVIN
inhibition is not controllable it is difficult to identify other
functions that SURVIVIN may have in the cell. In hematopoietic
cells, homozygous knockout of Birc5 in the hematopoietic
compartment was lethal however, hematopoietic stem cells
(HSCs) heterozygous for Birc5, survive and produce all cell
lineages excepting deficiencies in erythroid cells (Leung et al.,
2007). This suggests that SURVIVIN dosagemay be important for
its function. For these reasons, we developed a titratable
system for knockdown of SURVIVIN expression in hES cells.
Inhibition of SURVIVIN expression with either a doxycycline or
IPTG inducible shRNA resulted in a simultaneous decrease in
OCT4 andNANOG expression. IPTG-induced Sh18 targets all five
SURVIVIN splice variants and resulted in a loss of OCT4 and
NANOGmRNA. Interestingly, Sh20 does not target ΔEx3 but only
the other four SURVIVIN splice variants. Nevertheless induction
of Sh20 resulted in a significant decrease in all variants including
ΔEx3, as well as OCT4 and NANOG mRNA. We believe the
reduction in ΔEx3 expression observed in the Sh20 cell line is not
an off target effect but rather is a secondary consequence of
reduction in the other variants. We conclude that the loss of
OCT4 and NANOG expression is a downstream consequence of
the cellular changes (i.e., differentiation) that occurs due to
the inhibition of the four-targeted SURVIVIN variants and that
this same differentiation results in a decrease in ΔEx3
expression. In support of this hypothesis we demonstrate that
RA induced differentiation results in a rapid decline in ΔEx3
expression. These decreases were not observed following
expression of a scrambled control and loss of our ability to
inhibit SURVIVIN expression through silencing also resulted in
loss of the ability to inhibit OCT4 expression suggesting the
specificity of these results. OCT4, NANOG and SOX2 are the core
transcription factors associated with pluripotency. SURVIVIN
expression has previously been linked with OCT4 (Guo et al.,
2008; C. Li et al., 2012), and SOX2 (Lin et al., 2012) as inhibition
of these factors results in a decrease of SURVIVIN expression.
This interaction must be downstream of these transcription
regulators as they do not bind the BIRC5 promoter directly
(Boyer et al., 2005). Our results are the first time inhibition of
SURVIVIN has been linked to a decreased expression of these
pluripotency genes.
547A Role for the Oncofetal Protein SURVIVIN in PluripotencyThe mechanism by which SURVIVIN could affect OCT4 and
NANOG expression isn't known but at least two possibilities are
reasonable. Firstly, hES cells have a unique cell cycle
characterized by a very short G1 phase and a lacking or leaky
G1/S checkpoint. These cell cycle characteristics are linked to
maintenance of pluripotency by shortening the time that hES
cells are exposed to differentiation cues during G1 (Becker et
al., 2006). Indeed, it has been demonstrated that pharmaco-
logical activation of p53 followed by increased expression of p21
leads to accumulation of cells in G1 followed by hES cell
differentiation (Maimets et al., 2008). Transition from the G1 to
the S phase of the cell cycle is driven by cyclin dependent
kinases 4 and 6 (CDK4, CDK6). Their activity is dependent upon
the presence of their binding partners, CYCLINS, whose levels
oscillate throughout the cell cycle. CDK activity can be blocked
by binding of CDK inhibitory proteins belonging to INK4 family
(p15, p16, p18, p19) and CIP/KIP family (p21 and p27) that
directly inhibit CDK activity. SURVIVIN has been shown to
competitively interactwith p16Ink4a for CDK4 binding. Survivin is
a better binding partner for p16Ink4a than is CDK4. Conversely,
while SURVIVIN binds CYCLIN D it does so with less affinity than
CYCLIN D has for CDK4. The net result is that SURVIVIN titrates
the CDK4 inhibitor (p16Ink4a) preferentially from the CDK4
activator (CYCLIN D) (Suzuki et al., 2000) thus driving the cells
fromG1/S. Ectopic expression of a nuclear localized SURVIVIN in
HeLa cells increased CDK4, CYCLIN D, and phosphorylated pRB
protein levels as well as increasing G1/S progression (Connell et
al., 2008). Inhibition of SURVIVINmay increase the time spent in
G1 and therefore increase differentiation resulting in decreases
in OCT4 and/or NANOG.
Secondly, recent results have suggested that SURVIVIN may
also play a role in gene expression. Two groups have identified a
BIRC5 gene signature by altering BIRC5 expression in urinary
bladder (Salz et al., 2005) or in leukemic cells (Fukuda et al.,
2011) and comparing changes in gene expression. Salz et al.
(2005) overexpressed cDNA for SURVIVIN and identified 290
genes that were either upregulated (188 genes) or downregu-
lated (102 genes). Interestingly, if they overexpressed the T34A
SURVIVIN mutant they no longer observed these differences in
gene expression. Fukuda et al. (2011) deleted BIRC5 from
leukemic cells and identified 1096 genes differentially regulat-
ed. These studies do not directly link SURVIVIN to gene
regulation. The changes observed could simply be cellular
responses to the loss or gain of a required protein. Recently, a
more direct role in control of gene expression for SURVIVIN has
been demonstrated. SURVIVIN is normally exported out of the
nucleus by interaction with the export protein CRM1 (Stauber et
al., 2006). Wang et al. (2010) demonstrated that SURVIVIN can
be acetylated at K129 by the CREB-binding protein (CBP) and
this acetylation promotes SURVIVIN homodimer formation
minimizing its interaction with CRM1 thus SURVIVIN remains in
the nucleus. They demonstrated that SURVIVIN directly
interacts with Signal Transducer and Activator of Transcription
3 (STAT3) and modulates expression of STAT3 downstream
targets. SURVIVIN–STAT3 interaction did not affect DNA binding
but did differentially regulate expression of downstream
targets. This study is the first to show a direct role of
SURVIVIN in regulation of gene expression and thus SURVIVIN
could bemore directly linked to gene expression of pluripotency
genes. STAT3 is involved in the maintenance of pluripotency in
mouse ES cells (Niwa et al., 1998) but is dispensable in hES cells
(Daheron et al., 2004; Humphrey et al., 2004), therefore it isunlikely that this mechanism is responsible for the effects
observed in our results but it does suggest a similar mechanism
may be involved. Importantly, our results demonstrate that
SURVIVIN–ΔEx3 is highly expressed in hES cells. SURVIVIN–ΔEx3
is able to dimerize but does not have the interaction domain
for CRM1 that SURVIVIN and 2B have thus it is permanently
resident in the nucleus and could affect gene transcriptionmore
consistently.5. Conclusions
We have demonstrated that all SURVIVIN variants are expressed
at significantly higher levels in human ES cells than in
differentiated cells. We examined the subcellular localization
of the three most highly expressed variants which displayed
differential localization. We also used an inducible shRNA
system targeting SURVIVIN to inhibit expression in a titratable
fashion. Inhibition of SURVIVIN resulted in a concomitant
reduction in the expression of OCT4 and NANOG mRNA.
These results suggest that SURVIVIN may have a role in the
maintenance of pluripotency and further studies will be needed
to distinguish that role as well as the specific splice variant(s)
involved.
Supplementary data to this article can be found online at
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